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Efficacy of Inhaled Steroids in
Undiagnosed Subjects at High Risk for
COPD*
Results of the Detection, Intervention, and
Monitoring of COPD and Asthma Program
Mieke Albers, MSc; Tjard Schermer, MSc; Guido van den Boom, PhD;
Reinier Akkermans, MSc; Constant van Schayck, PhD;
Cees van Herwaarden, PhD, MD; and Chris van Weel, PhD, MD
Background and aim: COPD leads to a progressive decline of pulmonary function. Family
physicians treat a substantial number of patients with COPD and are encouraged to start
treatment at as early a stage as is possible. This study analyzed the effectiveness of early inhaled
corticosteroid treatment on the decline of pulmonary function in COPD patients.
Patients and setting: Subjects with a rapid decline in lung function (ie, FEV1 decline, > 80 mL/yr)
who had never before received a diagnosis of asthma or COPD.
Methods: Two-year, randomized, controlled, double-blind clinical trial of fluticasone propionate
(250 g bid; 24 patients) or placebo (25 patients), followed by a 7-month open-label study in
which all subjects received fluticasone propionate. The primary outcome was the post-broncho-
dilator therapy FEV1, and secondary outcomes were respiratory symptoms, exacerbations, health
state, quality of life, and health-care utilization.
Results: After 31 months, there were no statistical differences in post-bronchodilator therapy
FEV1 between the intervention group and the control group. No statistical differences were
observed for symptoms, exacerbations, or quality of life, although tendencies were consistently in
favor of treatment. There was no significant impact on the direct or indirect costs.
Conclusions: There are no indications that early treatment with inhaled corticosteroids modifies
a rapid decline in lung function or respiratory symptoms and quality of life.
(CHEST 2004; 126:1815–1824)
Key words: COPD; early treatment; inhaled corticosteroid; lung function decline
Abbreviations: BHR  bronchial hyperresponsiveness; CRQ chronic respiratory questionnaire; DIMCA Detec-
tion, Intervention, and Monitoring of COPD and Asthma; FP family physician; MCID minimal clinically important
difference; QALY quality-adjusted life year
COPD is becoming one of the leading causes ofdisability and death,1 and presents an increasing
burden of illness to society. In the past, considerable
underdiagnosis and undertreatment of chronic air-
way disease have been reported.2–4 At the same
time, several studies5–7 have reported promising
results with inhaled corticosteroid treatment. In
asthma patients, inhaled steroids are effective as
first-line therapy.8 In COPD patients, the beneficial
effects of inhaled steroids remain controversial.9,10
The annual rate of lung function decline is greater in
patients with COPD and asthma than in healthy
subjects.11–13 In patients with COPD, inhaled steroid
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tion during the first 6 months14–16 and some decel-
eration of lung function decline.17 Improvement of
health status14,18 and reduction of exacerbations14,19
also have been reported. These observations have
resulted in recommendations to start treatment as
early as possible.6 For asthma patients, this is in-
cluded in international guidelines,20 but for COPD
patients the beneficial effects of early treatment have
not yet been demonstrated. From our observation of
patients in the practice of family medicine, we
hypothesized that the maximum effect of inhaled
steroid treatment on lung function decline could be
expected if treatment was instituted at the earliest
stage of disease, before patients received diagnoses
in regular patient care.7 This resulted in the estab-
lishment of the Dutch Detection, Intervention, and
Monitoring of COPD and Asthma (DIMCA) in
family practice project in 1991.4,21 The identification
of early stages of COPD was later supported by the
Global Initiative for Chronic Obstructive Lung Dis-
ease classification with the stages 0 (at risk) and I
(mild disease).9,10 In the current study, we assessed
the effects of early inhaled steroid treatment in
subjects in whom COPD had not been diagnosed
who, prior to intervention, showed a rapid decline of
lung function. Subjects receiving early inhaled ste-
roid treatment were compared with subjects in
whom this treatment had been postponed for 2
years.
Materials and Methods
Design
Selection for the trial followed a screening and monitoring
approach of subjects who had never before received a diagnosis
and/or had been treated for asthma or COPD.4 All subjects aged
21 to 70 years fulfilling this criterion who were listed in 1 of the
10 family practices involved in the study were invited to the initial
screening program (Fig 1). All subjects completed a respiratory
symptoms questionnaire, and underwent spirometry and hista-
mine provocation testing. All subjects who reported at least one
respiratory symptom and showed airflow obstruction and/or
bronchial hyperresponsiveness (BHR) were invited to the second
study phase, which consisted of 6 to 24 months of monitoring
comprising four to eight lung function measurements. All sub-
jects with an annual pre-bronchodilator therapy FEV1 decline of
 80 mL were considered to be at risk for developing COPD and
were invited into the current study (Fig 1).
To study the effects of early inhaled steroid intervention, a
2-year, randomized, double-blind, placebo-controlled trial was
initiated (also referred to as early inhaled steroid treatment),
followed by an open-label extension period of 7 months (also
referred to as postponed inhaled steroid treatment). The alloca-
tion of subjects to the intervention and control groups followed a
block randomization within each family practice. Study medica-
tion (fluticasone propionate, 250 g bid administered by
metered-dose inhaler, and matching placebo) was prepared by
the manufacturer (GlaxoSmithKline; Research Triangle Park,
NC). Fluticasone and placebo were packed in identical canisters.
The patients’ family physician (FP) handed out a new set of study
medication every 3 months. To record drug compliance, the old
canisters were taken in and weighed. Subjects also recorded their
medication use in a trial diary. Individual compliance rates were
determined by expressing the number of puffs consumed (ie, the
dosages provided minus dosages returned) as a percentage of the
amount prescribed during the study.22 When noncompliance was
observed during trial visits, subjects were reminded of the need
to adhere to prescribed medication and were instructed in proper
use. Subjects were permitted to use short-acting bronchodilator
agents as rescue medication. In case of an exacerbation, a 10-day
course of therapy with oral prednisolone was advised.
Post-bronchodilator therapy FEV1 decline served as the pri-
mary outcome. During the monitoring phase preceding the trial,
the observed mean annual FEV1 decline for the subjects who
were eligible for study participation was  200 mL/yr. Halving
this rate to 100 mL/yr was considered a relevant treatment effect.
A per-protocol participation of 56 subjects (28 per group) was
required to detect this difference (assumptions: 1   0.80;
  0.05; SD 132 mL). Secondary outcomes were respiratory
symptoms, exacerbations, health state, quality of life, and health-
care utilization. The medical ethics review board of the Univer-
sity Medical Centre Nijmegen approved the study. Subjects gave
their written informed consent.
Measurements
Lung Function, Reversibility, and BHR: Lung function mea-
surements were performed in a lung function laboratory (Micro-
spiro HI-298 spirometer; Chest Corporation; Tokyo, Japan)24
following American Thoracic Society standards.23 Measurements
were scheduled at baseline and repeated every 6 months. The
European Community for Coal and Steel predicted values were
calculated.25 Reversibility was defined as a 10% change in the
FEV1 percentage of predicted value 15 min after the inhalation
of 800 g salbutamol by spacer. A histamine provocation test26
was performed to assess bronchial responsiveness. Subjects were
considered to have experienced BHR if the provocative dose of
histamine causing a 20% drop in FEV1 was  8 mg/mL.
Respiratory Symptoms and Exacerbations: Subjects recorded
the presence and severity of four respiratory symptoms (ie,
cough, shortness of breath, wheeze, and productive cough) on
diary cards. A weekly symptom score was calculated based on the
number of reported symptoms in the past week (minimum, 0;
maximum, 4). A week with a symptom score of 0 was defined as
a symptom-free week. An exacerbation was defined as an acute
episode that required medical attention during which at least two
of the following three criteria had to be fulfilled: increased
(productive) cough, and/or dyspnea, and/or wheezing; change in
sputum color; increased use of bronchodilators.7
Quality of Life and Health State:Disease-specific quality of life
was measured at baseline and every 6 months using the inter-
viewer-administered version of the chronic respiratory question-
naire (CRQ).29 A within-subject improvement of 0.5 U at the end
of the 2-year observation period was considered to be a minimal
clinically important difference (MCID).30 Preference-based util-
ities were measured every 6 months by standard gamble proce-
dure using the Maastricht utility measurement questionnaire.27
Quality-adjusted life years (QALYs) were determined by calcu-
lating the area under the utility-time curve for each subject. One
additional QALY is interpreted as one additional year in perfect
health for one subject.
Health-Care Resource Use and Productivity Losses
Consultations and prescriptions for respiratory medication
were recorded by the patients’ FPs and were verified by the
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investigators through medical record audit and a standardized
interview that was conducted every 3 months with study subjects.
Medication cost included pharmacy cost and the value added tax.
Subjects recorded their use of over-the-counter medications and
the number of days they had been unable to perform paid or
unpaid work in the diary. Indirect costs were assessed using the
Human Capital Approach. Dutch guilders were converted to
Euros (€). One day of lost work was valued as 8 h times €8.18 per
hour. For conversion to US dollars, Euros should be multiplied
by a factor 0.912, based on the 2000 Purchasing Power Parities,
as issued by the Organization for Economic Cooperation and
Development.
Statistical Analysis
Subjects who participated in the 2-year early intervention trial
and in the 7-month open-label extension with fluticasone treat-
ment, and who had used at least 70% of their trial medication
Figure 1. Flow chart of the initial general population cohort in the DIMCA program, and the trial
population derived from it. This article reports on the subjects having a rapid decline of FEV1 from the
original trials who were included in a per-protocol analysis.
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were included in a per-protocol analysis. Treatment groups were
compared on baseline characteristics using appropriate univariate
statistical tests. Because of the observed initial increase of the
post-bronchodilator therapy FEV1, a linear regression model
with one breaking point showed the best fit for the course of this
parameter over time. This so-called piecewise model was used to
analyze both early and postponed treatment effects. For early
treatment, the model discriminated between the initiation of
treatment (ie, 0 to 3 months) and ongoing treatment (ie, 4 to 24
months), and for postponed treatment it discriminated between
the initiation of treatment (ie, 24 to 26 months) and ongoing
treatment (ie, 27 to 31 months). The mean change in post-
bronchodilator therapy FEV1 over time was estimated by a mixed
linear effect model for repeated measurements,31 which included
baseline FEV1, age, gender, height, and smoking history as
covariates. The paired t test was used to compare the change per
period. Differences in symptom-free weeks and CRQ scores
were tested using t test statistics. The course of the CRQ total
and domain scores was analyzed using a mixed-effects model.
Poisson analysis was used to analyze the number of exacerbations.
Utilities were converted to QALYs by calculating the area under
the curve for the periods from 0 to 24 months and from 24 to 31
months. The mean differences in QALYs were tested using the t
test, and longitudinal analysis (a mixed-effects model with cor-
rection for baseline values) was used to estimate utility over time.
A statistical software package (SAS, version 6.12; SAS Institute;
Cary, NC) was used for all analyses.
Results
During the DIMCA monitoring phase, 85 subjects
with a rapid decline in lung function were identified
(Fig 1). Forty-one subjects were randomized to
receive early fluticasone treatment, and 44 subjects
were randomized to receive placebo treatment. Of
these subjects, 57 (67%) participated in the open-
label, postponed fluticasone study. The per protocol
analysis included all 49 subjects who finished both
the early treatment trial and the open-label extension
study, and were  70% compliant on trial medica-
tion use. The withdrawal, refusal, and noncompli-
ance of subjects did not show any selection bias
(results not presented). For the early fluticasone
treatment group (24 patients), the mean annual
decline prior to treatment was 210 mL (SD, 130
mL), and for the placebo group (25 patients) the
mean annual decline was 224 mL (SD, 134 mL). At
the start of the trial, the treatment groups were not
different in terms of age, post-bronchodilator ther-
apy FEV1, BHR, or reversibility (Table 1), but the
early treatment group included more ever-smokers
and had a history of more pack-years of smoking.
Clinical Effects
Lung Function: There were no statistically signif-
icant differences in the course of the post-bronchod-
ilator therapy FEV1 over time between the treat-
ment groups (Fig 2). The estimated mean changes of
the post-bronchodilator therapy FEV1 during the
subsequent study phases are shown in Table 2. For
other pulmonary function measures (ie, mean maximal
expiratory flow and inspiratory vital capacity), similar
patterns were found (data not shown). An explorative
subgroup analysis on smoking behavior, allergy, and
BHR, in addition to the rapid FEV1 decline, did not
modify the effect of those using fluticasone relative to
those using placebo (data not shown).
Respiratory Symptoms and Exacerbations: Dur-
ing the monitoring phase preceding the trial, eight
exacerbations were recorded in the group that was
later allocated to receive fluticasone treatment, and
three exacerbations occurred in the group that was
later allocated to receive placebo treatment. During the
Table 1—Baseline Characteristics of Study Subjects by
Treatment Group*
Characteristics
Treatment Groups
Fluticasone Propionate
(n  24)
Placebo
(n  25)
Age, yr 51.8 (10.3) 47.9 (10.0)
Female gender, % 58.3 40.0
Height, cm 168 (10) 172 (9)
Smoking history at entry
% ever 75.0 48.0
Pack-years† 9 (0.5–24) 0 (0–8)
Allergy, % 54.5 45.8
No bronchial symptoms
reported, %
37.5 52.0
Pre-bronchodilator therapy
FEV1
L 2.62 (0.75) 3.02 (0.66)
% predicted 88.3 (14.5) 91.2 (14.4)
Post-bronchodilator
therapy FEV1
L 2.73 (0.75) 3.10 (0.72)
% predicted 91.9 (12.0) 94.0 (14.8)
Post-bronchodilator
therapy FEV1/IVC
0.75 (0.06) 0.75 (0.07)
Reversibility of FEV1, %
predicted
2.93 1.62
PC20 histamine, mg/mL‡ 3.20 3.62
BHR, % 66.7 52.0
CRQ score§ 5.9 (0.86) 6.1 (0.79)
Dyspnea domain 6.2 (1.2) 6.5 (1.2)
Emotions domain 5.6 (0.9) 5.7 (0.9)
Fatigue domain 5.5 (1.1) 5.7 (1.1)
Mastery domain 6.3 (0.8) 6.6 (0.6)
Utility
Reference health state 0.55 (0.16) 0.61 (0.21)
Own health state 0.79 (0.17) 0.85 (0.13)
*Values given as mean (SD), unless otherwise indicated.
PC20  concentration of histamine provoking a fall in FEV1 of
 20%.
†Values given as median (interquartile range).
‡Values given as geometric mean.
§Range, 1 to 7.
Range, 0 to 1.
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early treatment trial, three exacerbations were re-
corded in the fluticasone group vs seven exacerbations
in the placebo group. During the open-label extension
period, one additional exacerbation was recorded in the
group that continued to receive fluticasone, and three
exacerbations in the postponed fluticasone treatment
group. Poisson analysis did not show a difference in
exacerbations between the groups for the subsequent
periods (p 0.18). Of the 25 exacerbations reported,
17 (68%) were first exacerbations.
During early treatment, the number of symptom-
free weeks did not differ between the early treat-
ment and postponed treatment groups (61.5% vs
71.5%, respectively; p 0.34). During postponed
treatment, these percentages were somewhat differ-
ent (early treatment group, 56.5% symptom-free
weeks; postponed treatment group, 76.5% symptom-
free weeks; p 0.06).
Quality of Life and Health State: Baseline CRQ
scores indicated a mild impairment in quality of life
(Table 1). During early treatment, there was no
difference between the treatment groups in either
the CRQ total score or the domain score (Fig 3). The
Table 2—Corrected Mean Change of the Annual Post-Bronchodilator Therapy FEV1 Decline as Estimated by the
(Piecewise) Regression Models*
Intervention
Randomized, Controlled,
Double-Blind Clinical Trial
Open-Label
Extension Study
0–3 mo 3–24 mo 24–27 mo 27–31 mo
Early fluticasone treatment
FEV1 decline, mL/yr 3.3 (101.2)  102.4 (265.5)
Continued early fluticasone treatment
FEV1 decline, mL/yr 115.4 (97.3)  24.1 (87.4)
Placebo treatment
FEV1 decline, mL/yr  29.9 (36.5)  10.0 (195.1)
Postponed fluticasone treatment
FEV1 decline, mL/yr 51.0 (57.9)  7.5 (69.6)
p value 0.52 0.41 0.51 0.54
*Values given as mean (SE).
Figure 2. Course of the mean post-bronchodilator therapy FEV1 during treatment. Bars indicate SEs.
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proportion of subjects with an MCID on the CRQ
was 21% in the early treatment group vs 24% in the
placebo group (p 0.79). The dyspnea score (25%
vs 12%, respectively), the fatigue score (21% vs 16%,
respectively), and the mastery domain scores (17% vs
8%, respectively) were consistently higher in the
fluticasone treatment group than in the placebo
treatment group (not statistically significant). For the
CRQ emotions domain, the proportion of subjects
was higher in the placebo group than in the flutica-
sone treatment group (25% vs 32%, respectively; not
statistically significant). After postponed treatment,
the proportions of subjects with an MCID in quality
of life were 14% for the postponed treatment group
and 33% for the early treatment group (p 0.12).
There were no significant differences in baseline
utilities between the subjects’ own health state and
the hypothetical health state (Table 1). During both
the early and postponed treatment, a large propor-
tion (ie, 36 to 45%) of the health state descriptions
collected did not indicate any impairment of generic
quality of life. The course of the mean utility of the
subject’s health status is shown in Figure 4. Early
treatment resulted in a mean difference of 0.0244 in
Figure 3. Disease-specific, health-related quality of life (the CRQ). Bars indicate SEs.
Figure 4. Preference-based valuations of the subjects’ own health status (standard gamble utilities).
Bars indicate SEs.
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favor of fluticasone (p 0.72; Table 3). Expressed in
QALYs, health state was indicative of the effect of
treatment. For early treatment, 1.22 QALYs were
gained per year per 100 treated subjects (95%
confidence interval, 5.5 to 7.9). Postponed treat-
ment resulted in a mean difference of 0.0038 in favor
of fluticasone treatment (p 0.87; Table 3). Ex-
pressed in QALY gains, this amounts to 0.76 QALYs
per year per 100 treated subjects (95% confidence
interval, 7.0 to 8.6). In the early treatment period,
the estimated mean difference in utility was 0.0099
per year (p 0.75). Assuming that this effect per-
sists in subsequent years, 0.99 QALYs would be
gained by early fluticasone intervention per 100
treated subjects per year.
Health-Care Resource Use: During early treat-
ment, the mean annual cost of experimental medi-
cation was €310 per subject (Table 4). The costs of
nonexperimental respiratory medication in the fluti-
casone group and the placebo group were €10.99
and €17.39, respectively (p 0.34). The average
number of prescriptions written per year for respiratory
medication was lower in the fluticasone treatment
group (0.70 prescriptions per subject) compared to that
in the placebo group (1.19 prescriptions per subject).
The total mean health-care cost was similar in both
groups (p 0.87). There were no referrals to chest
physicians or respiratory disease-related hospital admis-
sions. The cost of fluticasone treatment constituted the
major part of the direct health-care cost. The average
number of days that a subject had been unable to
perform his or her normal activities due to respiratory
symptoms was 3.1 days in the fluticasone group and 2.5
days in the placebo group. The associated mean indi-
rect cost was €203.05 and €164.52, respectively
(p 0.65). During postponed fluticasone treatment,
the cost of nonexperimental respiratory medication
remained higher (€8.03 vs €15.80, respectively;
p 0.15). The use of nonexperimental respiratory
medication during the trial (placebo treatment) ap-
peared to be highly correlated with the extent of use
during the extension period (postponed fluticasone
treatment; r 0.90). During postponed fluticasone
treatment, the average number of prescriptions per
year decreased, mainly in the early fluticasone treat-
ment group. The average cost of health-care resource
use remained constant (p 0.93), and there were no
referrals or hospital admissions. Loss of productivity
changed over time. In the early fluticasone treatment
group, the number of days lost showed a threefold
increase (p 0.05), whereas in the postponed treat-
ment group the increase was twofold (p 0.14). The
associated indirect costs were €589 and €334, respec-
tively. There was no significant difference in indirect
costs between the groups (p 0.27).
Discussion
In the DIMCA program, subjects in whom COPD
formerly had been undiagnosed but had objective
signs of COPD had their condition detected and
treated in a family practice. Although chronic airway
obstruction can be identified in such an early stage,
a final diagnosis, differentiating between asthma and
COPD, often is not yet possible. As subjects with
airway obstruction who show a rapid decline in lung
function bear an increased risk for the development
of COPD, this study focused on this particular
group. Following active detection, subjects were
treated at an earlier stage than would have been
possible in a regular general practice setting. In the
current study, the effect of treatment was measured
by the change in the course of post-bronchodilator
therapy FEV1. In conformance with our initial hy-
pothesis, lung function follow-up values were ana-
lyzed in a model that allows for differentiation
between the initial improvement of lung function
and the long-term mediation of the course of lung
function decline, in subjects receiving both early and
postponed treatment. However, there was no initial
improvement among the fluticasone-treated subjects
in the group of rapid decliners. Also, the hypothesis
that a delay in treatment would cause irreversible
damage could not be confirmed. The decline in lung
function in the early intervention group did not
differ from that after postponed intervention. A post
hoc power analysis based on the actual number of
trial participants (49 participants, instead of the
assumed 56 participants) revealed that with the
per-protocol participation of 49 subjects a treatment
difference of 105 mL/yr (80% power;   0.05; SD,
132 mL/yr) could have been detected.
Several early studies5,6 showing promising results
with inhaled steroid treatment expected maximum
benefit (ie, the prevention of the irreversible loss of
lung function) if treatment was instituted as early as
possible in the development of the disease. In a
metaanalysis,32 it was observed that patients with
Table 3—The (Piecewise) Calculated Gain in Health
State
Variable
Early Treatment Postponed Treatment
Placebo
(n  25)
Fluticasone
(n  24)
Postponed
Fluticasone
(n  23)
Early
Fluticasone
(n  23)
QALY gains 0.0890 0.1134* 0.0457 0.0419†
*p  0.72.
†p  0.87.
www.chestjournal.org CHEST / 126 / 6 / DECEMBER, 2004 1821
Downloaded From: http://journal.publications.chestnet.org/ by a Radboud Universiteit Nijmegen User  on 07/12/2012
clearly defined moderate-to-severe COPD had a
slowdown in the course of lung function decline
during 2 years of treatment with a relatively high
dosage of inhaled corticosteroids. A number of large
randomized clinical trials13,14,33,34 evaluating the ef-
ficacy of inhaled steroids have demonstrated initial
improvement in lung function. However, these stud-
ies13,14,33,34 confirmed the findings of our study that
inhaled steroid treatment does not substantially
modify the course of pulmonary function.
Although randomized at the start, the treatment
groups did not have a similar baseline health profile.
Subjects who were later allocated to early fluticasone
treatment had a slightly lower lung function and
showed less reversibility. Although not statistically
significant, they were found to be older, shorter,
more often allergic, less often without symptoms,
and more (often) to be smokers. This might indicate
that the early treatment group had a somewhat worse
prognosis at baseline. This is also illustrated by the
change in lung function (Table 1). Rapid decline in
lung function may be considered a strong indicator
of COPD; however, its (short-term) value in evalu-
ating treatment can be debated. Judged by the
percentage change in the two groups, however, the
actual gains in health in the two groups were quite
comparable.
At the time of planning this study (1992), change
in lung function was the predominant concept of the
outcome of COPD,5,17 and for that reason it was
chosen as the primary outcome measure. Nowadays,
it is recognized that a rapid decline is not the only
clinical characteristic of early stage COPD.10
The rationale for the early treatment of COPD is
its progressive nature and poor response to therapy
once the disease is fully developed. But its early
diagnosis is problematic, as the initial minimal symp-
toms and pulmonary function impairment are diffi-
cult to distinguish from self-limiting respiratory ill-
ness or asthma. For that reason, participants were
included in this study after an observed decline in
FEV1 of  80 mL/yr over 2 years, which is an
observation period during which other studies had
been able to find clinically relevant developments in
pulmonary function.32 Irreversible loss of pulmonary
function is characteristic of COPD, although (par-
tial) irreversibility is also seen in asthma. Some
patients in this study had BHR and were allergic,
which are features of asthma. However, BHR is also
often present in COPD patients.35
Today, the emphasis is less on pulmonary function
development as the outcome of the treatment of
COPD, but is more on symptoms, exacerbations,
health effects, and cost. However, in an exploratory
analysis these secondary effect measures did not
show a relevant effect of early fluticasone treatment.
There was no significant increase in QALYs, nor
were there any differences in exacerbation rate,
health-related quality of life, or respiratory symp-
toms. Considering the economic consequences,
Table 4—Average Cost (in Euros) for Early and Postponed Fluticasone Propionate Treatment*
Costs
0–24 mo 24–31 mo
Placebo Treatment
(n  25)
Early Fluticasone
Treatment (n  24)
Postponed Fluticasone
Treatment (n  25)
Continued Fluticasone
Treatment (n  24)
Units Cost Units Cost Units Cost Units Cost
Direct medical cost
Fluticasone propionate (trial medication)† 0.00 6.09 310.18 6.09 310.18 6.09 310.18
Bronchodilators‡ 0.61 9.30 0.18 3.27 0.46 7.00 0.14 1.45
Antibiotics‡ 0.26 3.54 0.20 2.48 0.13 2.64 0.14 3.55
Corticosteroids (noninhaled)‡ 0.07 0.46 0.22 2.62 0.14 0.85 0.07 0.94
Other prescribed respiratory medication‡ 0.26 3.03 0.09 0.57 0.20 1.84 0.00 0.00
OTC medication 1.04 2.04 3.10 2.09
FP consultation 0.34 5.96 0.32 5.35 0.33 5.52 0.31 5.36
Specialist consultation 0.00 0.00 0.00 0.00
Indirect cost
Days lost from work (unpaid) 2.51 164.52 3.10 203.05 5.09 333.59 9.00 588.98
Total cost
Fluticasone (trial medication)† 0.00 6.09 310.18 6.09 310.18 6.09 310.18
All respiratory medication 1.19 17.39 0.70 10.99 0.94 15.80 0.36 8.03
Direct medical 23.35 326.53 331.51 323.38
Indirect 2.51 164.52 3.10 203.05 5.09 333.59 9.00 588.98
Direct  indirect 187.87 529.58 665.11 912.36
*Costs are standardized to 1 year. OTC  over the counter.
†Based on daily doses cost.
‡Prescriptions.
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there was no difference in total mean health-care
cost or indirect cost. Incremental costs were pre-
dominantly due to the use of experimental medica-
tions. As subjects for this study were recruited in the
very early stage of their disease (before they had
received a diagnosis from a regular care physician),
room for improvement is likely to be small in any
disease-related outcome measure. However, several
tendencies on fluticasone treatment effects were
identified. Preceding intervention, more exacerba-
tions were recorded in the group that was later
allocated to fluticasone treatment. During flutica-
sone treatment, improvement was found in the
fluticasone group, suggesting a protective effect of
therapy with inhaled steroids on the exacerbation
rate. Furthermore, subjects in the postponed treat-
ment group reported more symptom-free weeks
after the initiation of fluticasone treatment. At base-
line, subjects rated their health as relatively good. In
both groups, there was a slight improvement in
health status, implying an in-care effect. Early treat-
ment did not show significant improvement in the
subjects’ health state, but the results were suggestive
for some health benefit. Furthermore, it was remark-
able that the difference in the use of nonexperimen-
tal respiratory medication was mainly due to bron-
chodilator use. In the placebo group, medication use
remained constant throughout the open-label exten-
sion period. This may reflect a person’s adaptation to
medication use. Between groups, the main differ-
ence in health-care utilization had to be attributed to
days lost from work, either paid or unpaid. After 2
years, the average number of days lost from work
increased in both groups, but mostly in the group
with early treatment. As these data do not allow for
a more advanced analysis, it remains unclear
whether subjects’ health became worse despite treat-
ment or whether group prognoses were different at
the start.
The DIMCA project is unique in that it has set out
to study subjects who were in the state of developing
COPD before signs and symptoms had brought
them to seek regular medical care. In this phase, no
effect from inhaled steroid treatment on lung func-
tion could be found. This implies that for this group
the delay in initiating treatment did not result in the
irreversible loss of lung function. On secondary
outcomes, the results of both early and postponed
treatment were suggestive of subtle health gains in
respiratory symptoms, exacerbation rate, and health
state. FPs therefore should continue to focus on the
early detection and treatment of those visiting them
who have respiratory signs and symptoms. But the
study did not present evidence of the benefits of
screening in order to begin treatment in the preclin-
ical phase of the disease.
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